US FDA approves Vertex’s Orkambi for cystic fibrosis in children
Pharmaceutical Technology
SEPTEMBER 5, 2022
The treatment is indicated for CF patients who are homozygous for the F508del mutation (F/F genotype) in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Earlier, the therapy had obtained FDA approval for usage in CF patients aged two years and above with two F508del mutation copies.
Let's personalize your content